ASH 2022 | Genomic determinants of resistance in patients with NDMM treated with targeted immunotherapy
In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses genomic determinants of resistance in patients with newly diagnosed multiple myeloma (NDMM) treated with targeted immunotherapy. In this study, whole genome sequencing (WGS) and single-cell sequencing were performed on bone marrow (BM) malignant plasma cells from patients with NDMM treated with the combination of carfilzomib, lenalidomide and dexamethasone (KRd) with daratumumab (MANHATTAN) or without daratumumab (NCT01402284). Results demonstrated several genomic alterations associated with resistance to agents used in quadruplet regimens. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Amgen: Research Funding; Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Pfizer: Consultancy.
